Open-label, Multicenter, Dose Escalation Phase Ia/Ib Study With Expansion Phase to Evaluate Safety, Pharmacokinetics and Activity of RO5509554, Administered as an Intravenous Infusion as Monotherapy and in Combination With Paclitaxel in Patients With Advanced Solid Tumors

Trial Profile

Open-label, Multicenter, Dose Escalation Phase Ia/Ib Study With Expansion Phase to Evaluate Safety, Pharmacokinetics and Activity of RO5509554, Administered as an Intravenous Infusion as Monotherapy and in Combination With Paclitaxel in Patients With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs Emactuzumab (Primary) ; Paclitaxel
  • Indications Advanced breast cancer; Bone cancer; Giant cell tumour of tendon sheath; Ovarian cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 01 Jul 2016 Status changed from recruiting to active, no longer recruiting.
    • 10 Jul 2015 Interim results published in the Lancet Oncology.
    • 02 Jun 2015 Interim results (n=44) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top